Page last updated: 2024-12-04

pyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pyridine is a heterocyclic aromatic organic compound with the formula C5H5N. It is a colorless liquid with a pungent odor. Pyridine is a weak base and is used in a variety of industrial applications, including the production of pesticides, pharmaceuticals, and dyes. It is also a common solvent and reagent in organic chemistry. Pyridine is found in coal tar and is also produced synthetically. Pyridine is a key component of many medications and is also used in the synthesis of various polymers and plastics. It is known to be toxic and can cause irritation to the skin, eyes, and respiratory system. Pyridine is an important compound in organic chemistry because it is a versatile building block for the synthesis of many other organic compounds. It is also a good ligand for metal ions, and its complexes are used in various catalytic reactions. Pyridine is a good solvent for a wide variety of organic compounds, and it is also used in many analytical techniques. The study of pyridine is important because it is a fundamental building block in many important molecules. It is also an important model system for understanding the properties of aromatic compounds. Pyridine is also used in a wide range of industrial applications, and its toxicity and environmental impact are important concerns. The study of pyridine is crucial for the development of new pharmaceuticals, pesticides, and other materials.'

azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1049
CHEMBL ID266158
CHEBI ID16227
MeSH IDM0081146

Synonyms (124)

Synonym
CHEBI:16227 ,
NCI60_006101
cp 32
un1282
epa pesticide chemical code 069202
pirydyna [polish]
ccris 2926
piridina [italian]
pyridin [german]
ai3-01240
caswell no. 717
fema no. 2966
rcra waste number u196
rcra waste no. u196
nsc 406123
fema number 2966
einecs 203-809-9
hsdb 118
pyridine, spectrophotometric grade, >=99%
inchi=1/c5h5n/c1-2-4-6-5-3-1/h1-5
nsc-406123
pirydyna
nci-c55301
nsc406123
wln: t6nj
pyridin
piridina
azine
NCGC00091476-01
pyridine ,
110-86-1
PYRIDINE-RING ,
C00747
azabenzene
pyridine, >=99%
nsc141574
nsc-141574
NCIOPEN2_002809
NCIOPEN2_007866
NCIOPEN2_007986
NCIOPEN2_007786
NCIOPEN2_007999
pyridine, puriss., absolute, over molecular sieve (h2o <=0.005%), >=99.8% (gc)
pyridine, anhydrous, 99.8%
0py ,
pyridine [un1282] [flammable liquid]
BMSE000432
CHEMBL266158
FT-0658212
FT-0654216
FT-0658683
Q0034
AKOS000120998
A802257
NCGC00091476-02
dtxsid9021924 ,
dtxcid101924
tox21_200960
cas-110-86-1
NCGC00258513-01
unii-nh9l3pp67s
nh9l3pp67s ,
ec 203-809-9
EPITOPE ID:140099
STL264195
pyridine [usp-rs]
ceftazidime impurity f [ep impurity]
ceftazidime pentahydrate impurity f [ep impurity]
pyridine [fhfi]
pyridine [iarc]
pyridine [hsdb]
pyridine [mi]
BP-13452
pyridine fraction
pyridine, acs reagent
pyridine-
un 1282
mfcd00011732
pyridine, hplc grade
J-002482
pyridine, puriss. p.a., acs reagent, >=99.8% (gc)
F0001-0227
pyridine, anhydrous
pyridine, suitable for hydroxyl value determination, >=99.5%
pyridine, >=99.5% (gc)
pyridine, purification grade, >=99.75%
pyridine, puriss., reag. ph. eur., dried, >=99.5% (gc), <=0.0075% water
pyridine, reagentplus(r), >=99%
pyridine, analytical standard
pyridine, acs reagent, >=99.0%
pyridine, jis special grade, >=99.5%
pyridine, biotech. grade, >=99.9%
pyridine, saj first grade, >=99.0%
pyridine, puriss. p.a., acs reagent, reag. ph. eur., >=99.5% (gc)
pyridine, for hplc, >=99.9%
EN300-17264
pyridine, ar, >=99.5%
pyridine, 99%
pyridine, pharmaceutical secondary standard; certified reference material
pyridine, p.a., acs reagent, 99.0%
pyridine, p.a., 99%
pyridine, lr, >=99%
pyridine; azabenzene; azine; cp 32; nsc 141574; nsc 406123
bdbm50176909
azabenzene; azine
BCP23599
Q210385
pyridine anhydrous
2-pyridine
3-pyridine
n-pyridine
[pyridine]
4-pyridine
hydropyridine
pyridine, anhydrous water 30ppm max
pyridine (15n)
pyridine (usp-rs)
pyridine (iarc)
ceftazidime pentahydrate impurity f (ep impurity)
ceftazidime impurity f (ep impurity)
pesticide code: 069202
pyridine 1 degree
pyridine ii
pyridine iii

Research Excerpts

Overview

Pyridine is a volatile solvent used as an intermediate in the production of insecticides, herbicides, pharmaceuticals, and dyes. Pyridine appears to be an excellent inducer of cytochrome P450 (CYP) 2E1.

ExcerptReferenceRelevance
"Pyridine is a prototypical inducer of cytochrome P450 (CYP) 2E1, an enzyme associated with cellular oxidative stress and membrane damage. "( Effects of pyridine exposure upon structural lipid metabolism in Swiss Webster mice.
Forshed, J; Goto, S; Hammock, BD; Newman, JW; Wheelock, CE, 2008
)
2.18
"Pyridine is a volatile solvent used as an intermediate in the production of insecticides, herbicides, pharmaceuticals, and dyes. "( Olfactory mucosal lesions in F344 rats following inhalation exposure to pyridine at threshold limit value concentrations.
Lewis, JL; Nikula, KJ, 1994
)
1.96
"Pyridine appears to be an excellent inducer of this isozyme in the lung and may be useful in studying xenobiotic metabolizing activities in this organ which are dependent upon this isozyme."( Induction by pyridine of cytochrome P450IIE1 and xenobiotic metabolism in rat lung and liver.
Carlson, GP; Day, BJ, 1992
)
1.37

Effects

Pyridine has been shown to cause liver and kidney damage in animals and in humans. Pyridine has unpleasant fishy odor with an odor index of 2390. Waste gaseous emissions containing pyridine require proper treatment before discharge.

ExcerptReferenceRelevance
"As pyridine has 1C-N, 1C=N, and no N-N bond, it photodegrades easily as compared to 1 N-N and 2C=N bonds of pyridazine of lowest photodecomposition rate."( Photocatalytic degradation of N-heterocyclic aromatics-effects of number and position of nitrogen atoms in the ring.
Kaur, J; Pal, B, 2013
)
0.9
"Pyridine has unpleasant fishy odor with an odor index of 2390 and waste gaseous emissions containing pyridine require proper treatment prior to discharge."( Biotreatment of waste gas containing pyridine in a biofilter.
Mudliar, SN; Mukherji, SS; Padoley, KV; Pandey, RA; Rajvaidya, AS; Subbarao, TV; Vaidya, AN, 2007
)
1.33
"Pyridine has been shown to be an effective inducer of the ethanol-inducible cytochrome P-450IIE1 in both liver and lung. "( Effect of pyridine on the hepatic and pulmonary metabolism of 2-butanol in rat and rabbit.
Carlson, GP; Page, DA, 1993
)
2.13
"Pyridine has been shown to cause liver and kidney damage in animals and in humans. "( Stimulation of aniline, p-nitrophenol and N-nitrosodimethylamine metabolism in kidney by pyridine pretreatment of rabbits.
Adali, O; Arinç, E; Gençler-Ozkan, AM, 2000
)
1.97
"Pyridine has been shown to induce hepatic microsomal cytochrome P450IIE1 and dependent activities. "( Induction by pyridine of cytochrome P450IIE1 and xenobiotic metabolism in rat lung and liver.
Carlson, GP; Day, BJ, 1992
)
2.1
"Pyridine has been shown to be a much more potent inhibitor than other solvents of the metabolism and therefore the clastogenicity of benzene. "( Pyridine prevents the clastogenicity of benzene but not of benzo[a]pyrene or cyclophosphamide.
Harper, BL; Legator, MS, 1987
)
3.16

Treatment

Pyridine treatment increased the P450 content of the kidney 1.6-fold (P<0.05) Pyridine treatment upregulated CYP1A1 mRNA and its protein in the lung, kidney and liver in female rats.

ExcerptReferenceRelevance
"Pyridine treatment also resulted in an increase in reactivity with monoclonal antibodies directed against CYP 1A1, 2B1 and 3A."( Evidence for multiple inducible cytochrome P450 isozymes in SENCAR mouse skin by pyridine.
Agarwal, R; Bickers, DR; Jugert, FK; Khan, SG; Merk, HF; Mukhtar, H, 1994
)
1.24
"Pyridine treatment negatively modulated heme saturation of hepatic TPO."( Coordinate up-regulation of CYP1A1 and heme oxygenase-1 (HO-1) expression and modulation of delta-aminolevulinic acid synthase and tryptophan pyrrolase activities in pyridine-treated rats.
Alam, J; Fung, J; Ghosal, A; Iba, MM; Thomas, PE; Touchard, C, 1999
)
1.22
"Pyridine treatment upregulated CYP1A1 mRNA and its protein in the lung, kidney and liver in female rats, and upregulated the mRNA but not the protein in the lung and liver in male rats."( Constitutive and induced expression by pyridine and beta-naphthoflavone of rat CYP1A is sexually dimorphic.
Fung, J; Iba, MM; Park, Y; Thomas, PE,
)
1.12
"Pyridine treatment also elevated P450 contents of liver and lung by 2.04- and 1.4-fold, respectively."( Induction of N-nitrosodimethylamine metabolism in liver and lung by in vivo pyridine treatments of rabbits.
Adali, O; Arinç, E; Gençler-Ozkan, AM, 2000
)
1.26
"Pyridine treatment increased the P450 content of the kidney 1.6-fold (P<0.05)."( Stimulation of aniline, p-nitrophenol and N-nitrosodimethylamine metabolism in kidney by pyridine pretreatment of rabbits.
Adali, O; Arinç, E; Gençler-Ozkan, AM, 2000
)
1.25
"treatment with pyridine (75 mg/kg per day) or beta-naphthoflavone (betaNF; 25 mg/kg per day) for two consecutive days and analyzed catalytically (via O-dealkylation of resorufin ethers), at the protein level (by Western blot analysis) and at the mRNA level (by Northern blot analysis)."( Constitutive and induced expression by pyridine and beta-naphthoflavone of rat CYP1A is sexually dimorphic.
Fung, J; Iba, MM; Park, Y; Thomas, PE,
)
0.74

Toxicity

ExcerptReferenceRelevance
" The results with PiBx suggest that either the parent compound possesses some direct cytotoxicity or that a toxic metabolite was generated through a biotransformation pathway not inhibited by PiBx."( 3,5-Dichloroaniline toxicity in Fischer 344 rats pretreated with inhibitors and inducers of cytochrome P450.
Brown, PI; Lo, HH; Rankin, GO; Valentovic, MA, 1995
)
0.29
"The involvement of Cd(II) in toxic manifestations and pathological aberrations in lower and higher organisms entails interactions with low and high molecular mass biological targets."( pH-specific aqueous synthetic chemistry in the binary cadmium(II)-citrate system. Gaining insight into cadmium(II)-citrate speciation with relevance to cadmium toxicity.
Bino, A; Dakanali, M; Karligiano, N; Kefalas, ET; Kyrikou, I; Mavromoustakos, T; Panagiotidis, P; Raptopoulou, CP; Salifoglou, A; Terzis, A, 2005
)
0.33

Pharmacokinetics

ExcerptReferenceRelevance
" Plasma half-life of pyridine was 7 h following a single 100 mg/kg dose of the compound, and 8 h following the last dose of a 3-day, 8 h/day exposure to a 200 ppm inhalation dose of the compound."( Pharmacokinetics of and CYP1A induction by pyridine and acetone in the rat: interactions and effects of route of exposure.
Iba, MM; Scholl, HR, 1997
)
0.88
" Pharmacokinetic investigations have shown the drug to be highly bound to blood proteins, mainly serum albumin, and to have a low brain uptake, explaining its lack of sedative effects."( Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
Carrupt, PA; Jolliet, P; Morin, C; Morin, D; Pagliara, A; Rihoux, JP; Testa, B; Tillement, JP; Urien, S, 1998
)
0.3
" Large interindividual variations were observed in the pharmacokinetics of Cpd-D in male Sprague-Dawley (SD) rats, which were subsequently divided into two phenotypes; >6-fold longer terminal-phase half-life and ∼10-fold larger AUC0-∞ values were observed in slow metabolizers (SM) than in fast metabolizers (FM) after the oral administration of Cpd-D."( Interindividual variations in metabolism and pharmacokinetics of 3-(6-methylpyridine-3-yl-sulfanyl)-6-(4H-[1,2,4]triazole-3-yl-sulfanyl)-N-(1,3-thiazole-2-yl)-2-pyridine carboxamide, a glucokinase activator, in rats caused by the genetic polymorphism of C
Chiba, M; Eiki, J; Hasegawa, T, 2014
)
0.63
" More importantly, 4aa showed much better pharmacokinetic properties than SGX-523."( Novel [1,2,4] Triazol [4,3-a] Pyridine Derivatives as Potential Selective c-Met Inhibitors with Improved Pharmacokinetic Properties.
Fang, L; Gou, S; Liang, Y; Zhang, X; Zhao, J, 2017
)
0.74

Compound-Compound Interactions

ExcerptReferenceRelevance
" To simplify sample preparation, in situ derivatization using methyl chloroformate was combined with ultrasound-assisted emulsification microextraction."( A new analytical method to determine non-steroidal anti-inflammatory drugs in surface water using in situ derivatization combined with ultrasound-assisted emulsification microextraction followed by gas chromatography-mass spectrometry.
Jeong, KM; Lee, CH; Lee, J; Nam, MW; Shin, Y, 2014
)
0.4
"With the idea that platinum compounds that bind with DNA differently than cisplatin may be better-able to overcome platinum resistance in ovarian tumor, the monofunctional platinum complex tris(imidazo(1,2-α)pyridine) chloroplatinum(II) chloride (coded as LH6) has been synthesized and investigated for its activity, alone and in combination with the phytochemicals curcumin and quercetin, against human ovarian A2780, A2780(cisR) and A2780(ZD0473R) cancer cell lines."( Monofunctional Platinum-containing Pyridine-based Ligand Acts Synergistically in Combination with the Phytochemicals Curcumin and Quercetin in Human Ovarian Tumour Models.
Arzuman, L; Beale, P; Huq, F; Yu, JQ, 2015
)
0.88

Bioavailability

Pyridine derivative (49) displayed 100% oral bioavailability in mice and delivered a 96% parasite burden reduction when dosed at 50 mg/kg. Oxidation of the pyridine ring nitrogen, combined with alkylation at the two position, led to a compound with an excellent in vitro activity profile.

ExcerptReferenceRelevance
" Oxidation of the pyridine ring nitrogen, combined with alkylation at the two position, led to a compound with an excellent in vitro activity profile as well as oral bioavailability in both rats and dogs."( Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists.
Bugianesi, RL; Cheng, K; Creighton, M; Cui, J; Goulet, MT; Lo, JL; Mao, AH; Mount, GR; Ponpipom, MM; Ren, RN; Simeone, JP; Vincent, SH; Yang, YT; Yudkovitz, JB, 2002
)
0.97
" The previously reported calpain inhibitor SJA6017 (1) showed oral efficacy in a retinal pharmacological model, but its oral bioavailability was low due to the metabolic lability and low water-solubility."( Exploration of orally available calpain inhibitors. Part 3: Dipeptidyl alpha-ketoamide derivatives containing pyridine moiety.
Miyashita, H; Shirasaki, Y; Yamaguchi, M, 2006
)
0.55
"We report the design and synthesis of a series of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as orally bioavailable small molecule inhibitors of renin."( Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.
Bryant, J; Cai, C; Ciske, FL; Collard, W; Collins, R; Day, J; Edmunds, JJ; Ferreira, S; Gu, C; Holsworth, DD; Jalaie, M; Mastronardi, M; McConnell, P; Mennen, K; Mochalkin, I; Powell, NA; Ryan, MJ; Van Huis, CA; Zhang, E, 2007
)
0.34
" In particular, the analogues 30d, 30c, 31c, and 36d exhibited much higher solubility and bioavailability than that of itraconazole."( Design and synthesis of pyridine-substituted itraconazole analogues with improved antifungal activities, water solubility and bioavailability.
Cao, X; He, H; Liu, X; Liu, Y; Liu, Z; Yang, Y, 2011
)
0.68
"An unusually large data set of 397 piperazinyl-glutamate-pyridines/pyrimidines as potent orally bioavailable P2Y(12) antagonists for inhibition of platelet aggregation was studied for the first time based on the combination of three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, and molecular dynamics (MD) methods."( Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Hao, M; Li, G; Li, Y; Wang, Y; Yan, Y; Yang, L; Zhang, S, 2011
)
0.84
" In a pharmacokinetic study, good metabolic stability and oral bioavailability of 31 were achieved in rats, dogs, and monkeys."( Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.
Hamaguchi, H; Hatanaka, K; Higashi, Y; Inami, M; Inoue, T; Kunikawa, S; Moritomo, A; Mukoyoshi, K; Nakai, K; Nakajima, Y; Sasaki, H; Shirakami, S; Takahashi, F; Tanaka, A; Usuda, H, 2015
)
0.67
" The project team was able to improve the bioavailability by reducing efflux through systematic modifications to the strength of the HBA by changing the electronic properties of neighboring groups, whilst maintaining sufficient acceptor strength for potency."( Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
Eisman, MS; Gu, C; Harrison, RA; Hu, H; Johannes, JW; Kazmirski, S; Lamb, ML; Lyne, PD; Mikule, K; Peng, B; Scott, DA; Su, N; Sylvester, MA; Wang, W; Ye, Q; Zheng, X, 2016
)
0.43
"Fluorination is a well-known strategy for improving the bioavailability of drug molecules."( 5-Fluoroimidazo[4,5-b]pyridine Is a Privileged Fragment That Conveys Bioavailability to Potent Trypanosomal Methionyl-tRNA Synthetase Inhibitors.
Buckner, FS; Fan, E; Gelb, MH; Gillespie, JR; Hol, WG; Huang, W; Hulverson, MA; Koh, CY; Nguyen, J; Pendem, N; Ranade, RM; Shibata, S; Verlinde, CL; Zhang, Z, 2016
)
0.75
" Pharmacokinetic experiments show oral bioavailability through gastric absorption."( Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization.
Cescon, DW; Hansen, MD; Hoj, JP; Siddiqui-Jain, A, 2018
)
0.75
" Since excess hemoglobin in the plasma causes reduced nitric oxide (NO) bioavailability and oxidative stress, we hypothesized that esophageal contraction may be impaired by intravascular hemolysis."( Impairment of Nitric Oxide Pathway by Intravascular Hemolysis Plays a Major Role in Mice Esophageal Hypercontractility: Reversion by Soluble Guanylyl Cyclase Stimulator.
Beraldi Calmasini, F; Costa Alexandre, E; Fernanda Franco-Penteado, C; Ferreira Costa, F; Henrique Silva, F; Yotsumoto Fertrin, K, 2018
)
0.48
" Since compound 1k displayed favorable bioavailability in mouse cassette dosing PK study, we conducted in vivo Pharmacodynamics (PD) studies of this compound."( Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Asano, M; Maezaki, H; Mizojiri, R; Nii, N; Sasaki, M; Satoh, Y; Sumi, H; Yamamoto, Y, 2019
)
0.77
"The discovery of orally bioavailable FXIa inhibitors has been a challenge."( Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.
Bozarth, JM; Corte, JR; Fang, T; Gilligan, PJ; Harper, TW; Jeon, Y; Lam, PYS; Lou, Z; Luettgen, JM; Myers, JE; Osuna, H; Rossi, KA; Seiffert, DA; Sheriff, S; Wexler, RR; Wu, Y; Zheng, JJ, 2020
)
0.56
" One promising pyridine derivative (49) displayed 100% oral bioavailability in mice and delivered a 96% parasite burden reduction when dosed at 50 mg/kg in a Leishmania donovani mouse model of visceral leishmaniasis."( Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.
Braillard, S; Chatelain, E; Cooper, CB; Denny, WA; Franzblau, SG; Gupta, S; Launay, D; Ma, Z; Maes, L; Marshall, AJ; O'Connor, PD; Thompson, AM; Wan, B; Yardley, V, 2021
)
0.97

Dosage Studied

Ceftazidime can be at body temperature for 4-10 h, resulting in potentially varying rates of degradation to pyridine by-product. Until the outcomes of this in vitro study are confirmed by appropriate in vivo studies, continuous dosing of ceftzadime-Dianeal admixtures for the treatment of PDAP may be preferred.

ExcerptRelevanceReference
" In contrast, hepatic 2E1 poly(A)+ RNA levels failed to increase following these same dosing regimens, suggesting that metabolic alterations, such as those associated with starvation, were not etiologic factors in renal 2E1 induction."( Evidence for elevation of cytochrome P4502E1 (alcohol-inducible form) mRNA levels in rat kidney following pyridine administration.
Kim, H; Kim, SG; Lee, MY; Novak, RF, 1992
)
0.5
") administered 18 h prior to dosing with EC decreased the binding of [14C-ethyl]EC to cellular macromolecules."( The effect of pyridine on the in vitro and in vivo metabolism of ethyl carbamate (urethane) by rat and mouse.
Carlson, GP; Page, DA, 1994
)
0.65
"The phenomenon of supercooperativity in platelet aggregation is manifested by the occurrence of clear-cut thresholds in dose-response relationships; in such cases the Hill coefficient has unusually high values."( Supercooperativity in platelet aggregation: substituted pyridyl isoxazoles, a new class of supercooperative platelet aggregation inhibitors.
Demina, OV; Shram, SI; Varfolomeev, SD; Vrzheshch, PV, 1994
)
0.29
" PY caused a dose-dependent elevation of hepatic CYP2B1/B2B levels in rats, which ranged from 4- to 22-fold over the dosing regimen of 100 to 400 mg PY/kg/day, for 3 days, respectively."( Enhanced expression of rat hepatic CYP2B1/2B2 and 2E1 by pyridine: differential induction kinetics and molecular basis of expression.
Hollenberg, PF; Kim, H; Novak, RF; Putt, D; Reddy, S, 1993
)
0.53
" Mice in the 1000 and 2000 mg kg(-1) dose groups were comatose following dosing and died within 24 h of dose administration."( Pyridine does not induce unscheduled DNA synthesis (UDS) in hepatocytes of male B6C3F1 mice treated in vivo.
Hamilton, CM; Kubicek, JE; MacGregor, JA; Mirsalis, JC,
)
1.57
" Studies of olfaction did not support unusual sensitivity, defined as lower odor thresholds, among MCS subjects; however, a dose-response pattern of symptoms was observed in response to suprathreshold concentrations of phenyl ethyl alcohol."( Controlled exposures to volatile organic compounds in sensitive groups.
Fiedler, N; Kipen, HM, 2001
)
0.31
" Tumor growth inhibition was observed during the dosing interval, and the tumors regrew when compound administration was ceased."( Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
Bouska, JJ; de Jong, R; Giranda, VL; Gramling-Evans, EE; Guan, R; Han, EK; Johnson, EF; Klinghofer, V; Leverson, JD; Li, Q; Li, T; Liu, X; Luo, Y; Mamo, M; McGonigal, TP; Mika, AK; Mitten, MJ; Nguyen, PT; Oleksijew, A; Oltersdorf, T; Powlas, JA; Rosenberg, SH; Shi, Y; Shoemaker, AR; Smith, RA; Stoll, VS; Thomas, SA; Woods, KW; Zinker, BA, 2005
)
0.33
" All derivatives produced a bell-shaped dose-response curve and none of the compounds were active at the D2 receptor alone, which indicates that the mechanism behind the activity of both the pyridine based mimetics and PLG is the same."( Synthesis and evaluation of novel pyridine based PLG tripeptidomimetics.
Del Tredici, AL; Kihlberg, J; Luthman, K; Saitton, S; Saxin, M; Stenström, T, 2008
)
0.82
" Syrian hamsters were dosed with pyridine (400mg/kg) intraperitoneally with and without silymarin (200mg/kg daily by gavage) for 4 days."( Pyridine induction of cytochrome P450 1A1, iNOS and metallothionein in Syrian hamsters and protective effects of silymarin.
Citil, M; Erginsoy, S; Karapehlivan, M; Sozmen, M; Tunca, R; Yapar, K, 2009
)
2.08
" When the dosage of BABC was 10."( [Removal of pyridine using suspended and attached growing bacterium of Paracoccus denitrificans W12].
Chen, LJ; Liu, JJ; Wen, DH; Yu, R; Zhao, C, 2010
)
0.74
" A number of these novel oximes have shown the ability to decrease the level of ChE inhibition in the brains of rats treated with a high sublethal dosage of either a sarin surrogate (nitrophenyl isopropyl methylphosphonate, NIMP) or the VX surrogate NEMP."( Efficacy of novel phenoxyalkyl pyridinium oximes as brain-penetrating reactivators of cholinesterase inhibited by surrogates of sarin and VX.
Chambers, HW; Chambers, JE; Funck, KE; Meek, EC; Pringle, RB; Ross, MK, 2016
)
0.43
" Since compound 1k displayed favorable bioavailability in mouse cassette dosing PK study, we conducted in vivo Pharmacodynamics (PD) studies of this compound."( Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
Asano, M; Maezaki, H; Mizojiri, R; Nii, N; Sasaki, M; Satoh, Y; Sumi, H; Yamamoto, Y, 2019
)
0.77
"Until these results are confirmed with appropriate in vivo studies, intermittent intraperitoneal dosing of ceftazidime admixed with icodextrin should be used with caution and appropriate clinical monitoring or a suitable alternative antibiotic should be used."( High Pyridine Generation in Ceftazidime-Icodextrin Admixtures Used to Treat Peritoneal Dialysis-associated Peritonitis.
Castelino, RL; Harmanjeet, H; Jose, MD; Kaur, H; Patel, RP; Peterson, GM; Sud, K; Wanandy, T, 2019
)
1.03
" Depending on the type of PD solution, ceftazidime is exposed to an environment with acidic or basic pH, and depending on the type of dosing and individual unit practices related to preparation and storage, ceftazidime can be at body temperature for 4-10 h, resulting in potentially varying rates of degradation to pyridine by-product."( Pyridine levels in ceftazidime - peritoneal dialysis admixtures stored at body temperature.
Castelino, RL; Harmanjeet, H; Jose, MD; Nguyen, TT; Patel, RP; Peterson, GM; Sud, K; Wanandy, T; Zaidi, STR, 2020
)
2.17
"86% glucose) PD solutions to obtain a concentration of 125 mg/L (continuous dosing model) or 500 mg/L (intermittent dosing model)."( Pyridine levels in ceftazidime - peritoneal dialysis admixtures stored at body temperature.
Castelino, RL; Harmanjeet, H; Jose, MD; Nguyen, TT; Patel, RP; Peterson, GM; Sud, K; Wanandy, T; Zaidi, STR, 2020
)
2
"Until the outcomes of this in vitro study are confirmed by appropriate in vivo studies, continuous dosing of ceftzadime-Dianeal admixtures for the treatment of PDAP may be preferred over continuous dosing of ceftazidime-Physioneal admixtures, and intermittent dosing of ceftazidime-Physioneal and ceftazidime-Dianeal admixtures, as ceftazidime remains stable and the generated levels of pyridine are below the maximum recommended daily exposure."( Pyridine levels in ceftazidime - peritoneal dialysis admixtures stored at body temperature.
Castelino, RL; Harmanjeet, H; Jose, MD; Nguyen, TT; Patel, RP; Peterson, GM; Sud, K; Wanandy, T; Zaidi, STR, 2020
)
2.17
" One promising pyridine derivative (49) displayed 100% oral bioavailability in mice and delivered a 96% parasite burden reduction when dosed at 50 mg/kg in a Leishmania donovani mouse model of visceral leishmaniasis."( Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.
Braillard, S; Chatelain, E; Cooper, CB; Denny, WA; Franzblau, SG; Gupta, S; Launay, D; Ma, Z; Maes, L; Marshall, AJ; O'Connor, PD; Thompson, AM; Wan, B; Yardley, V, 2021
)
0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
NMR chemical shift reference compoundAny compound that produces a peak used to reference an NMR spectrum during data pre-processing.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
mancude organic heteromonocyclic parent
monocyclic heteroarene
azaarene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase II - Conjugation of compounds73122
Methylation1338
histamine biosynthesis421
rutin degradation230

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency7.94330.004023.8416100.0000AID485290
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.15220.000214.376460.0339AID720692
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.012119.739145.978464.9432AID1159509
lethal factor (plasmid)Bacillus anthracis str. A2012Potency1.25890.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)4,000.00000.00011.753610.0000AID1304509
Nicotinate phosphoribosyltransferaseHomo sapiens (human)Ki0.00080.00000.00060.0019AID1618606
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)Kd4,500.00000.01300.45650.9000AID1304506
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (21)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
response to oxidative stressNicotinate phosphoribosyltransferaseHomo sapiens (human)
NAD salvageNicotinate phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (26)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
nicotinate phosphoribosyltransferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
transferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
metal ion bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
extracellular regionNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
azurophil granule lumenNicotinate phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (48)

Assay IDTitleYearJournalArticle
AID1149238Dissociation constant, pKa of the compound1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID26563compound was evaluated for rate constant of transfer (log K1) at pH 7.41998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID213129Inhibition of Thromboxane synthetase at 100 uM1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives.
AID26287Partition coefficient (logD3.0)1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID342464Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
The many roles for fluorine in medicinal chemistry.
AID168703Inhibition of Rana pipiens muscle activity.1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID159270Toxicity determined using Microtox Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID343680Hexadecane-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID343682Hexadecane-water partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID687185Dissociation constant, pKa of the compound at pH 11 to 12 by spectrophotometric analysis2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.
AID1474182Basic dissociation constant, pKa of the compound2017Journal of medicinal chemistry, 05-11, Volume: 60, Issue:9
The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID701844Dissociation constant, pKa of the compound2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Mitigating heterocycle metabolism in drug discovery.
AID1304509Inhibition of C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as 7-benzyloxy-4-(trifluoromethyl)coumarin O-debenzylation pretreated 2 mins followed by NADPH addition by fluorometric method in prese2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.
AID1304506Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as spectral dissociation constant by spectrophotometric method2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.
AID1145387Partition coefficient, log P of the compound by HPLC analysis1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID1145386Partition coefficient, log P of the compound by shake-flask technique1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Direct measurement of octanol-water partition coefficients by high-pressure liquid chromatography.
AID419115Binding affinity to heme assessed as binding constant for stepwise binding of 2 equivalent of drug to 1 molecule of heme in presence of 40% DMSO by UV-visible spectroscopy2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID728444Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102H double mutant expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 1 mM at pH 5.4 by circular dichroism analysis2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID419119Binding affinity to heme assessed as binding constant for stepwise binding of 2 molecules of heme to 1 equivalent of drug in presence of 12 mM SDS by UV-visible spectroscopy2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID644414Lipophilicity, log D of the compound in octanol-water at pH 7.4 by reverse-phase HPLC analysis2012Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4
QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).
AID343398Octanol-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID1576430Dissociation constant, pKa of the compound2019MedChemComm, Nov-01, Volume: 10, Issue:11
The cytotoxic potential of cationic triangulenes against tumour cells.
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID728443Binding affinity to Enterobacteria phage T4 lysozyme harboring L99A/M102H double mutant expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 1 mM at pH 6.8 by circular dichroism analysis2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1148664Octanol-water partition coefficient, log P of the compound1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Phosphorus-nitrogen compounds. 22. Synthesis and antitumor activity of arylsulfonylhydrazone analogues.
AID419118Binding affinity to heme assessed as binding constant for stepwise binding of 2 equivalent of drug to 1 molecule of heme in presence of 12 mM SDS by UV-visible spectroscopy2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID346867Binding affinity to heme in 12 mM SDS surfactant assessed as equilibrium constant by UV-visible spectrophotometry2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century.
AID26548compound was evaluated for reverse occurs for the rate constant(log K-1) at pH 7.41998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID30391Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 3.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1304507Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as rate constant for first phase2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1304508Binding affinity to C-terminal four-histidine tagged human CYP3A4delta3 to 24 residues expressed in Escherichia coli assessed as change in melting temperature at 10 uM by spectrophotometric method2016Journal of medicinal chemistry, 05-12, Volume: 59, Issue:9
Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.
AID419116Binding affinity to heme assessed as binding constant for stepwise binding of 2 molecules of heme to 1 equivalent of drug in presence of 40% DMSO by UV-visible spectroscopy2009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID30390Compound was evaluated for its ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-9-10e-111985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1321514Dissociation constant, pKa of the compound2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
AID3436812,2,4-trimethylpentane-water partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,710)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990501 (18.49)18.7374
1990's136 (5.02)18.2507
2000's679 (25.06)29.6817
2010's1201 (44.32)24.3611
2020's193 (7.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 90.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index90.00 (24.57)
Research Supply Index7.93 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index164.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (90.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.11%)5.53%
Reviews52 (1.87%)6.00%
Case Studies1 (0.04%)4.05%
Observational0 (0.00%)0.25%
Other2,729 (97.99%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]